| Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition MR Sapienza, F Fuligni, C Agostinelli, C Tripodo, S Righi, MA Laginestra, ... Leukemia 28 (8), 1606-1616, 2014 | 171 | 2014 |
| Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue S Ciavarella, MC Vegliante, M Fabbri, S De Summa, F Melle, G Motta, ... Annals of Oncology 29 (12), 2363-2370, 2018 | 113 | 2018 |
| Blastic plasmacytoid dendritic cell neoplasm: state of the art and prospects MR Sapienza, A Pileri, E Derenzini, F Melle, G Motta, S Fiori, A Calleri, ... Cancers 11 (5), 595, 2019 | 96 | 2019 |
| Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target MR Sapienza, F Abate, F Melle, S Orecchioni, F Fuligni, M Etebari, ... haematologica 104 (4), 729, 2019 | 71 | 2019 |
| The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies A Gazzola, C Mannu, M Rossi, MA Laginestra, MR Sapienza, F Fuligni, ... Therapeutic advances in hematology 5 (2), 35-47, 2014 | 67 | 2014 |
| Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734 F Spriano, E Gaudio, L Cascione, C Tarantelli, F Melle, G Motta, V Priebe, ... Blood advances 4 (17), 4124-4135, 2020 | 52 | 2020 |
| Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified MA Laginestra, L Cascione, G Motta, F Fuligni, C Agostinelli, M Rossi, ... Modern Pathology 33 (2), 179-187, 2020 | 42 | 2020 |
| Pathogenetic and diagnostic significance of microRNA deregulation in peripheral T-cell lymphoma not otherwise specified MA Laginestra, PP Piccaluga, F Fuligni, M Rossi, C Agostinelli, S Righi, ... Blood Cancer Journal 4 (11), e259-e259, 2014 | 35 | 2014 |
| Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant–associated anaplastic large cell lymphomas V Tabanelli, C Corsini, S Fiori, C Agostinelli, A Calleri, S Orecchioni, ... Human Pathology 90, 60-69, 2019 | 30 | 2019 |
| Distinctive histogenesis and immunological microenvironment based on transcriptional profiles of follicular dendritic cell sarcomas MA Laginestra, C Tripodo, C Agostinelli, G Motta, S Hartmann, C Döring, ... Molecular cancer research 15 (5), 541-552, 2017 | 30 | 2017 |
| Prognostic impact of TP53 mutation in newly diagnosed diffuse large B‐cell lymphoma patients treated in the FIL‐DLCL04 trial A Chiappella, F Diop, C Agostinelli, M Novo, L Nassi, A Evangelista, ... British Journal of Haematology 196 (5), 1184-1193, 2022 | 20 | 2022 |
| AIRC 5xMille consortium ‘Genetics-driven targeted management of lymphoid malignancies and the Italian Registry on Blastic Plasmacytoid Dendritic Cell Neoplasm. Molecular … MR Sapienza, F Fuligni, C Agostinelli, C Tripodo, S Righi, MA Laginestra, ... Leukemia 28 (8), 1606-1616, 2014 | 19 | 2014 |
| Genome-wide miRNA expression profiling of molecular subgroups of peripheral T-cell lymphoma W Lone, A Bouska, S Sharma, C Amador, M Saumyaranjan, TA Herek, ... Clinical Cancer Research 27 (21), 6039-6053, 2021 | 17 | 2021 |
| Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma A Rossi, S Orecchioni, P Falvo, V Tabanelli, E Baiardi, C Agostinelli, ... Leukemia 36 (1), 197-209, 2022 | 14 | 2022 |
| Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma N Leupin, PL Zinzani, F Morschhauser, S Dalle, M Maerevoet, JM Michot, ... Cancer 128 (5), 1004-1014, 2022 | 13 | 2022 |
| Genomic alterations of ribosomal protein genes in diffuse large B cell lymphoma E Derenzini, C Agostinelli, A Rossi, M Rossi, F Scellato, F Melle, G Motta, ... British journal of haematology 185 (2), 330-334, 2019 | 12 | 2019 |
| Peripheral T-cell lymphoma, not otherwise specified: clinical manifestations, diagnosis, and future treatment SA Pileri, V Tabanelli, S Fiori, A Calleri, F Melle, G Motta, D Lorenzini, ... Cancers 13 (18), 4535, 2021 | 11 | 2021 |
| Predictive and prognostic molecular factors in diffuse large B-cell lymphomas SA Pileri, C Tripodo, F Melle, G Motta, V Tabanelli, S Fiori, MC Vegliante, ... Cells 10 (3), 675, 2021 | 11 | 2021 |
| A three-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma E Derenzini, S Mazzara, F Melle, G Motta, M Fabbri, R Bruna, ... Haematologica 106 (9), 2405, 2021 | 10 | 2021 |
| NR1H3 (LXRα) is associated with pro‐inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b‐cell lymphoma MC Vegliante, S Mazzara, GM Zaccaria, S De Summa, F Esposito, F Melle, ... Hematological Oncology 40 (5), 864-875, 2022 | 9 | 2022 |
